Long-term Follow-up of Metaphyseal Sclerotic Lines in Children Treated with Pamidronate = 파미드로네이트 치료받은 환자에서 발생한 골간단 경화성 선에 대한 장기간 추적 연구

다국어 초록 (Multilingual Abstract)

Purpose: Bisphosphonates are widely used for the management steroid-induced osteoporosis (SIO) in children. With the increasing use of bisphosphonates, there have been reports of abnormal radiological findings in the growing skeleton. Therefore, their use in pediatric patients remains controversial. The present study was conducted to evaluate the long-term follow-up radiographic features, particularly metaphyseal sclerotic lines, in children who receive pamidronate therapy for nephropathy. Methods: Twenty-four children with nephropathy treated with oral calcium and pamidronate (mean duration, 9 months; dose, 100 mg daily), were evaluated retrospectively. All patients had SIO secondary to chronic glucocorticoid therapy for treating nephropathy. Long bone radiographic imaging was performed before treatment with pamidronate, and at follow-up, several years later. Physeal growth rates were estimated by measuring the distance that the sclerotic lines moved on the radiographs during the corresponding time intervals. Results: The mean follow-up period was 138 months. Long bone radiographs showed well-defined sclerotic lines at the metaphyseal ends, progressively moving from the physeal plate to the diaphysis, in all patients. The mean rate of movement of the sclerotic line was 6.21 mm per year. In 12 patients, the lines disappeared. The mean rate of growth in height was 7.33 cm per year. Conclusions: Results of long-term follow-up suggest that the metaphyseal sclerotic lines associated with pamidronate treatment tend to disappear without affecting overall skeletal growth. Bisphosphonate treatment for SIO in children with nephropathy seems to be safe, although further studies in larger number of patients are needed.

참고문헌 (Reference)

• 1 Al Muderis M, "Zebra lines of pamidronate therapy in children" 89 : 1511-1516, 2007
• 2 Barros ER, "Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation" 21 : 811-818, 2008
• 3 Rauch F, "Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis" 19 : 1191-1193, 2004
• 4 Hong IK, "Scintigraphic findings of growth arrest lines after bisphosphonate administration in a steroid-induced osteoporosis patient: a case study" 35 : 740-742, 2010
• 5 Devogelaer JP, "Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta" 16 : 360-363, 1987
• 6 Onwuneme C, "Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis" 92 : 1087-, 2007
• 7 Grissom LE, "Radiographic features of bisphosphonate therapy in pediatric patients" 33 : 226-229, 2003
• 8 Silverman SL, "Rachitic syndrome after disodium etidronate therapy in an adolescent" 75 : 118-120, 1994
• 9 Zacharin M, "Pamidronate treatment of osteogenesis imperfecta-- lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response" 15 : 163-174, 2002
• 10 Kim SD, "Pamidronate therapy for preventing steroidinduced osteoporosis in children with nephropathy" 102 : 81-87, 2006
• 11 Suresh S, "Metaphyseal bands in osteogenesis imperfect" 20 : 42-44, 2010
• 12 Brumsen C, "Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis" 76 : 266-283, 1997
• 13 Fujiwara I, "Intravenous pamidronate treatment in osteogenesis imperfecta" 157 : 261-262, 1998
• 14 Lewiecki EM, "International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry" 89 : 3651-3655, 2004
• 15 Ogden JA, "Growth slowdown and arrest lines" 4 : 409-415, 1984
• 16 Gonzalez E, "Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta" 14 : 529-533, 2001
• 17 Sumnik Z, "Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry" 61 : 137-142, 2004
• 18 Glorieux FH, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta" 339 : 947-952, 1998
• 19 Samuel R, "Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease" 94 : 385-389, 1994
• 20 Dimeglio LA, "A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta" 18 : 43-53, 2005